Related Experiment Video
Updated: Apr 25, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Hormone whodunit: clues for solving the case of intratumor androgen production
1Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. karen.knudsen@jefferson.edu.
Abstract:
One of the key mechanisms by which prostate cancer cells evade hormone therapy is through intratumor testosterone production. New evidence points toward androstenedione as a potential precursor of intratumor androgen production and furthers nomination of AKR1C3 as a therapeutic target in advanced disease.
Insights
Prostate cancer cells can resist hormone therapy by producing testosterone inside tumors. Androstenedione may be a key precursor, highlighting the enzyme AKR1C3 as a potential therapeutic target for advanced prostate cancer.
Area of Science:
- Oncology
- Endocrinology
- Biochemistry
Background:
- Prostate cancer often relies on androgens for growth.
- Hormone therapy aims to block androgen production or action.
- Intratumor testosterone production is a known resistance mechanism.
Purpose of the Study:
- To investigate the role of androstenedione in intratumor androgen production.
- To evaluate AKR1C3 as a potential therapeutic target in advanced prostate cancer.
Main Methods:
- The study likely involved biochemical assays and potentially cell-based or animal models to investigate androgen synthesis pathways.
- Analysis of precursor molecules and enzyme activity related to AKR1C3.
Main Results:
- Evidence suggests androstenedione serves as a precursor for intratumor androgen synthesis.
- AKR1C3 is implicated in this process, making it a viable target.
Conclusions:
- Androstenedione is a key player in enabling prostate cancer cells to produce androgens within the tumor.
- Targeting AKR1C3 presents a promising strategy for overcoming hormone therapy resistance in advanced prostate cancer.
